AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SOUTH SAN FRANCISCO, Calif & BEIJING–(BUSINESS WIRE)–
AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate Twist Bioscience next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed’s portfolio of tests designed to provide insight into the genetic predisposition and treatment regimens for patients, providing a more targeted therapeutic approach.
“The partnership between Twist and AcornMed provides us with access to the global leader in high quality DNA synthesis at scale and quality. Twist understands the importance of panel performance and consistency when using genetic analysis to inform clinical treatment,” said Dr. Feng Lou, CTO and co-founder of AcornMed. “As NGS testing becomes a more mainstream, and widely adopted technology to enable precision medicine, we believe AcornMed’s products will be widely embraced to positively transform patient treatment and drive down the associated costs of health economics in China.”
“Twist Bioscience’s proprietary DNA manufacturing process and quality control will play an increasingly important role in the development of in vitro diagnostic (IVD) panels, aiding in the adoption of NGS as a precision medicine tool. This is one of the reasons AcornMed selected Twist,” continued Dr. Lou. “As AcornMed begins to move testing into the IVD field, we can feel confident that the results will meet and exceed the NMPA’s expectations for patient assessment and diagnosis.”
“We are pleased to enable AcornMed, an innovative and patient focused company, to accelerate their mission of providing exceptional precision medicine solutions for cancer identification and treatment,” said Emily Leproust, CEO and co-founder of Twist Bioscience. “The ability to stratify patients to assist in treatment based on their cancers’ genetic makeup represents a critical factor for the future of medicine.”
AcornMed Biotechnology Co., Ltd. (AcornMed) is an innovation-driven National High-Tech Enterprise in China. With the head office located in Beijing Economic-Technological Development Area, AcornMed has established two R&D centers in Beijing and Tianjin, with a total area of 5,000 square Meters.
Based on the self-developed big data platform for genomic analysis, AcornMed provides comprehensive solution of cancer precision medicine with genomics technologies. As a leading next generation sequencing (NGS) corporation in solid tumors and hematological malignancies, AcornMed has built a solid brand reputation in lung cancer, gastrointestinal tumors, urologic cancer, leukemia, and lymphoma. Over 30 clinical testing products have been launched and the application scenarios…